（文章来源：证券日报） 证券日报网讯 2月26日，嘉应制药在互动平台回答投资者提问时表示，截至2026年2月13日，公司合并 普通账户和融资融券信用账户持有人数为26579户。 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2026-002 广东嘉应制药股份有限公司 关于员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为保证公司 2024 年员工持股计划的顺利实施，保障持有人的合法权益，根 据公司《2024 年员工持股计划（修订稿）》《2024 年员工持股计划管理办法（修 订稿）》的有关规定，同意设立公司 2024 年员工持股计划管理委员会（以下简 称"管理委员会"），作为 2024 年员工持股计划的管理机构，监督本员工持股计 划的日常管理。管理委员会由 5 名委员组成，设管理委员会主任 1 名，管理委 员会委员的任期为 2024 年员工持股计划的存续期。 表决结果：同意 31,744,300 份，占出席持有人会议的持有人所持份额总数 的 100%；反对 0 份；弃权 0 份。 （二）审议通过《关于选举公司 2024 年员工持股计划管理委员会委员的议 案》 根据《2024 年员工持股计划管理办法》的有关规定，经持有人会议审议， 同意选举廖敏、贺杏、曹科骏、蒋坤、韩通为公司 2024 年员工 ...

Core Viewpoint - The company has approved an employee stock ownership plan (ESOP) aimed at enhancing employee engagement and aligning their interests with shareholders through stock ownership [1][2]. Group 1: Employee Stock Ownership Plan Approval - The company held a board meeting on December 12, 2024, and a shareholder meeting on December 30, 2024, to approve the ESOP and related management measures [1]. - The board authorized the management to handle matters related to the ESOP implementation [1]. Group 2: Stock Buyback Details - The company plans to repurchase between 7 million and 13.5 million shares of its A-shares, with a maximum buyback price of 9.80 yuan per share, totaling up to 132.3 million yuan [2]. - The actual buyback completed was 10,396,000 shares, costing approximately 69.99 million yuan [2]. Group 3: Fundraising and Subscription Details - The ESOP aims to raise a total of up to 46.68 million yuan, with a subscription price of 4.49 yuan per share, allowing for the purchase of up to 10.396 million shares [4]. - The actual funds raised amounted to 31.74 million yuan, with 29 employees participating in the subscription [4]. Group 4: Share Transfer and Accounting - As of February 12, 2026, 7,070,000 shares were transferred to the ESOP account, representing 1.393% of the company's total share capital [5]. - The company will follow accounting standards for share-based payments to assess the impact of the ESOP on its financial results [7]. Group 5: Independence and Governance - The first major shareholder did not participate in the ESOP, ensuring no conflict of interest [6]. - The ESOP holders are independent from the company's major shareholders and management, with a governance structure that prevents any single holder from exerting significant influence [6].

以上内容基于公开资料整理，不构成投资建议。 经济观察网嘉应制药（002198）2025年年度报告预计于2026年4月28日披露。公司股权结构存在不稳定 性，第一大股东持股比例较低，可能引发控股权变动风险。 ...

关于员工持股计划非交易过户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2024 年 12 月 12 日召 开第七届董事会第四次临时会议、于 2024 年 12 月 30 日召开公司 2024 年第三 次临时股东大会，审议通过了《关于＜公司 2024 年员工持股计划（草案）＞及 其摘要的议案》《关于＜公司 2024 年员工持股计划管理办法＞的议案》《关于提 请股东大会授权董事会办理公司 2024 年员工持股计划相关事宜的议案》，同意 公司实施员工持股计划，并授权董事会办理与本次持股计划相关的事宜。公司 于 2025 年 10 月 15 日召开第七届董事会第九次临时会议，审议通过了《关于调 整 2024 年员工持股计划相关事项的议案》，同意对公司员工持股计划相关事项 进行调整。具体内容详见公司在巨潮资讯网（http://www.cninfo.com.cn）披露的 相关公告。 根据《中华人民共和国公司法》《中华人民共和国证券法》《关于上市公司 实施员工持股计划试点的指导意见》《深圳证券交易所上市公司自律 ...

Group 1 - The core viewpoint of the article is that Jiaying Pharmaceutical has experienced an expansion in operating cash flow due to business development and adjustments in sales credit policies [1] Group 2 - Investors inquired about the reasons behind the continuous expansion of Jiaying Pharmaceutical's operating cash flow and where the expenditures are allocated [1] - Jiaying Pharmaceutical responded that the changes in operating cash flow are related to business activities and adjustments in sales credit policies [1]

Core Viewpoint - The company, Jiaying Pharmaceutical, reported that as of December 31, 2025, the total number of holders in its combined ordinary and margin trading accounts is expected to reach 24,806 [1] Summary by Category Company Information - Jiaying Pharmaceutical has engaged with investors through an interactive platform, providing insights into its account holder projections [1] - The company anticipates a significant number of account holders by the end of 2025, indicating potential growth in investor interest and engagement [1] Industry Context - The increase in account holders may reflect broader trends in the pharmaceutical industry, where investor participation is crucial for funding and growth [1] - The company's proactive communication with investors may set a precedent for transparency and engagement within the industry [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Market Performance - The Chinese medicine sector rose by 0.35% on December 25, with Wanbangde leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Gainers in Chinese Medicine Sector - Wanbangde (002082) closed at 13.42, up 10.00% with a trading volume of 221,500 shares and a transaction value of 286 million yuan [1] - ST Changyao (300391) closed at 1.53, up 5.52% with a trading volume of 469,000 shares and a transaction value of 71.61 million yuan [1] - Huasen Pharmaceutical (002907) closed at 15.57, up 4.01% with a trading volume of 62,100 shares and a transaction value of 96.15 million yuan [1] Market Trends and Capital Flow - The Chinese medicine sector experienced a net outflow of 130 million yuan from institutional investors, while retail investors saw a net inflow of 163 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Wanbangde had a net inflow of 30.98 million yuan from institutional investors, but a net outflow of 30.35 million yuan from retail investors [3] - Jiaying Pharmaceutical (002198) saw a net inflow of 16.25 million yuan from institutional investors, while retail investors had a net outflow of 9.67 million yuan [3] - Kangmei Pharmaceutical (600518) experienced a net inflow of 15.73 million yuan from institutional investors, with retail investors withdrawing 4.15 million yuan [3]

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. has launched an international promotion plan centered on its classic Hakka medicine product "Shuangliao Houfeng San" during a promotional event in Hong Kong, aiming to promote Hakka medicine to global Hakka communities [1][18]. Group 1: Cultural Significance and Product Overview - The cultural significance of Hakka medicine is highlighted, emphasizing its unique system formed over centuries by integrating traditional Chinese medicine wisdom and regional experiences, with "Shuangliao Houfeng San" being a prime example [3][20]. - The product adheres to principles of using authentic medicinal materials and precise preparation, establishing a comprehensive quality control system, thus representing both Hakka cultural heritage and clinical efficacy [3][20]. Group 2: Strategic Initiatives and Collaborations - The choice of Hong Kong as the initial launch site leverages its position as a cultural crossroads and its robust pharmaceutical regulatory framework to facilitate global outreach for Hakka medicine [4][21]. - A strategic cooperation agreement was signed between Jiaying Pharmaceutical and the Global Value Investment Association to collaboratively develop an international innovation framework for Hakka medicine [11][28]. Group 3: Market Development and Future Plans - The company presented a detailed analysis of its sales policies and international expansion plans, focusing on the cultural value, brand rejuvenation, and market models for "Shuangliao Houfeng San" in global health scenarios [7][24]. - Future collaborations will focus on optimizing distribution channels, enhancing brand building, and promoting product innovation, aiming for a win-win outcome through resource integration between Guangdong and Hong Kong [9][26]. Group 4: Industry Insights and Recommendations - Experts discussed the implementation paths and challenges of the Hakka medicine internationalization plan, providing actionable suggestions for product promotion, competitive differentiation, and research topics [12][29]. - The event served as a platform for the systematic international dissemination of Hakka medicine culture, with Jiaying Pharmaceutical positioning "Shuangliao Houfeng San" as a cultural carrier to showcase the unique value of traditional Chinese medicine on a global stage [16][33].